MD Anderson Cancer Center, The University of Texas
Welcome,         Profile    Billing    Logout  
 16 Trials 
24 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fu, Siqing
NCT05036681: A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma

Recruiting
2
30
US
Futibatinib, Pembrolizumab
M.D. Anderson Cancer Center, National Comprehensive Cancer Network
Metastatic Cancer, Endometrium Cancer, Endometrial Carcinoma
12/24
12/24
H-200-001, NCT04180215 / 2019-000907-34: A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

Recruiting
1/2
200
Europe, US
HB-201 intravenous administration., HB-202 intravenous administration alternating with HB-201 intravenous administration., HB-201 intravenous administration + standard of care regimen including pembrolizumab., HB-202 / HB-201 alternating intravenous administration + pembrolizumab., HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab., HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)
Hookipa Biotech GmbH, Hookipa Biotech
HPV-Related Squamous Cell Carcinoma
06/25
06/26
NCT06385925: A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Recruiting
1/2
150
US
TSN1611
Tyligand Bioscience (Shanghai) Limited
Malignant Neoplasm
10/26
04/27
TTX-MC138-002, NCT06260774: Study of TTX-MC138 in Subjects With Advanced Solid Tumors

Not yet recruiting
1/2
20
US
TTX-MC138
TransCode Therapeutics
Advanced Solid Tumor
02/26
02/27
NCT04902040: Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Recruiting
1/2
12
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Plinabulin, NPI-2358, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
M.D. Anderson Cancer Center
Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Merkel Cell Carcinoma, Advanced Renal Cell Carcinoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Stage III Bladder Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Bladder Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
06/25
06/25
KEYNOTE-D88, NCT05572684: A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors

Recruiting
1/2
131
US
NC410, pembrolizumab, KEYTRUDA®
NextCure, Inc., Merck Sharp & Dohme LLC
Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer, Esophageal Cancer, Endometrial Cancer, Head Neck Cancer, Cervical Cancer, Lung Cancer
07/25
11/25
NCT06056323: A Study of HB0045 Injection in Patients With Advanced Solid Tumors

Recruiting
1/2
71
US
HB0045 Drug Product, fixed dose combination of two antibodies targeting two different epitopes (N-terminal and catalytic site) of CD73
Shanghai Huaota Biopharmaceutical Co., Ltd., Gabrail Cancer Center Research, Dana-Farber Cancer Institute, M.D. Anderson Cancer Center
Solid Tumor, Adult
09/25
03/26
BA3021-001, NCT03504488: CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

Recruiting
1/2
420
Europe, US, RoW
CAB-ROR2-ADC, BA3021, PD-1 inhibitor
BioAtla, Inc.
Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer
12/25
12/25
NCT03756818: TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors

Completed
1
52
US
Mivavotinib, Spleen Tyrosine Kinase Inhibitor TAK659, syk Inhibitor TAK-659, syk Inhibitor TAK659, syk-Inhibitor TAK-659, syk-Inhibitor TAK659, TAK-659 Free Base, TAK659 Free Base, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pharmacokinetic Study, PHARMACOKINETIC, PK Study
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Ovarian Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Ovarian Carcinoma
02/23
02/23
NCT05036291: A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors

Recruiting
1
120
US
NB004 tablets, Sotorasib
Ningbo Newbay Technology Development Co., Ltd
Advanced Solid Tumor
02/25
06/25
NCT03784677: A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors

Completed
1
11
US
TRPV6 Calcium Channel Inhibitor SOR-C13, SOR-C13
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Refractory Ovarian Carcinoma, Refractory Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
06/23
06/23
NCT03646071: A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors

Recruiting
1
80
US
RX108
NeuPharma, Inc.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
08/23
12/23
NCT04192344: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor

Recruiting
1
85
US
ABSK021
Abbisko Therapeutics Co, Ltd
Neoplasms, Tenosynovial Giant Cell Tumor
12/23
12/23
NCT05300438: Phase I Study of TSN084 in Patients With Advanced Malignant Tumors.

Recruiting
1
74
US
TSN084
Tyligand Bioscience (Shanghai) Limited
Cancer (With or Without Metastasis)
03/25
06/25
NCT05038839: Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors

Recruiting
1
44
US
Cabozantinib, Pamiparib, BGB-290, PARP Inhibitor BGB-290
M.D. Anderson Cancer Center
Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
06/24
06/24
NCT05704985: Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

Recruiting
1
60
US
DK210 (EGFR), Radiation therapy, Immune checkpoint blockers, Pembrolizumab, Nivolumab, Chemotherapy, Paclitaxel, Carboplatin, Oxaliplatin, Fluorouracil, Capecitabine
DEKA Biosciences
Cancer, Solid Tumor, Colorectal Cancer, Pancreas Cancer, Non Small Cell Lung Cancer, Head and Neck Cancer, Gynecologic Cancer, Skin Cancer, Kidney Cancer
09/24
02/25
NCT06365918: Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis

Not yet recruiting
1
21
US
VG2025
M.D. Anderson Cancer Center
Advanced Solid Tumor, Carcinomatosis
03/28
03/30
GRN300-001, NCT04711161: First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.

Suspended
1
73
US
GRN-300, SIK2/3 Inhibitor, Paclitaxel, Taxane
Green3Bio, Inc.
Ovarian Tumors
12/24
03/25
NCT05018273: Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors

Active, not recruiting
1
60
Europe, US
VB10.NEO, Atezolizumab, Tecentriq
Nykode Therapeutics ASA, Genentech, Inc., Vaccibody AS
Solid Tumors, Adult
12/24
12/24
NCT05266612: Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors

Recruiting
1
12
US
VG2025, Nivolumab Injection [Opdivo]
Virogin Biotech Canada Ltd
Solid Tumor
12/24
12/25
NCT05989724: A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

Recruiting
1
150
US
SON-DP
Qurgen Inc.
Solid Tumor, Breast Cancer, Pancreatic Cancer, Ovarian Cancer, Colorectal Cancer
09/25
03/26
NCT06028373: A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas

Recruiting
1
48
US
ATG-031
Antengene Biologics Limited
Advanced Solid Tumors, B-cell Non-Hodgkin Lymphomas
12/25
06/26
NCT03203525: Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

Recruiting
1
52
US
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-fluorouracil, 5-Fluracil, 5-FU, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin, folinic acid, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Pegylated Liposomal Doxorubicin Hydrochloride, ATI-0918, Caelyx, DOX-SL, Doxil, Doxilen, Doxorubicin HCl Liposomal, Doxorubicin HCl Liposome, Doxorubicin Hydrochloride Liposome, Duomeisu, Evacet, LipoDox, Lipodox 50, Liposomal Adriamycin, Liposomal Doxorubicin Hydrochloride, Liposomal-Encapsulated Doxorubicin, Pegylated Doxorubicin HCl Liposome, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, TLC D-99, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel, Tumor Treating Fields Therapy, Alternating Electric Field Therapy, TTF, TTFields
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Advanced Malignant Neoplasm, Colorectal Carcinoma Metastatic in the Liver, Metastatic Malignant Neoplasm in the Liver, Refractory Malignant Neoplasm
12/26
12/26
NCT05075993: Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

Recruiting
1
352
US
LVGN3616 + LVGN6051 + Nab-Paclitaxel, LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide, LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel, LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide
M.D. Anderson Cancer Center, Lyvgen Biopharma Holdings Limited
Metastatic Esophageal, Gastric Cancer, Metastatic Head and Neck Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic HPV Related Solid Tumors, Metastatic Ovarian Carcinoma, Metastatic Soft Tissue Sarcoma, Metastatic Uveal Melanoma
02/27
02/27

Download Options